雷公藤多苷片/雷公藤片治疗类风湿关节炎临床实践指南解读
该指南由中医、西医风湿病专家、药师及循证方法学家共同制定,基于临床证据与专家经验(循证、共识、经验补充)形成推荐与专家建议,系统总结雷公藤多苷片和雷公藤片治疗类风湿关节炎的临床适应证、用法、用量、联合用药及安全性,为规范应用提供专业指导。
要点
- 雷公藤多苷片与雷公藤片是治疗类风湿关节炎的常用有效中成药,已纳入2019版国家医保药品目录。
- 两药活性成分可能具有毒性、治疗窗窄且说明书描述可能不详尽,临床需规范使用以降低无效治疗与副作用风险。
- 指南推荐与专家建议涵盖临床适应证、用法用量、联合用药及安全性,应结合证据等级与推荐强度应用。
核心结论
- 该指南基于临床研究证据与专家经验(循证、共识、经验补充)形成推荐与专家建议,系统总结雷公藤多苷片和雷公藤片治疗类风湿关节炎的临床适应证、用法、用量、联合用药及安全性,为规范应用提供专业指导。
研究设计与样本
- 指南制定组邀请中医与西医风湿病领域临床专家、药师及循证医学方法学家,共同筛选临床问题、确定证据水平与推荐强度并形成推荐和良好实践要点。
主要发现
- 雷公藤多苷片和雷公藤片是治疗类风湿关节炎常用且有效的代表性雷公藤制剂,均已纳入2019版国家医保药品目录。
- 患者对两药的反应存在个体差异,临床应用可能不规范,导致治疗无效及副作用风险。
- 雷公藤活性成分可能具有毒性,两药说明书可能描述不详尽且治疗窗窄,亟需标准化临床实践指南。
关键数值与推荐
- 有临床证据支持的临床问题形成推荐,无临床证据支持的临床问题形成专家建议。
- 推荐与专家建议系统总结雷公藤多苷片和雷公藤片治疗类风湿关节炎的临床适应证、用法、用量、联合用药及安全性。
临床怎么用
- 临床使用雷公藤多苷片或雷公藤片治疗类风湿关节炎时,应参照指南推荐与专家建议规范适应证、用法用量及联合用药。
- 需关注两药潜在毒性、窄治疗窗及个体差异,加强安全性监测以降低副作用风险。
局限性
- 原文未报告指南制定中具体检索范围、证据等级体系及推荐强度分级标准。
- 原文未报告各推荐条款的具体内容、剂量数值及安全性监测指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tripterygium wilfordii Hook F (TwHF) is one of the most commonly used and effective traditional Chinese herbal medicines against rheumatoid arthritis (RA). Both Tripterygium Glycoside Tablets (TGT) and Tripterygium wilfordii Tablets (TWT) are the representative TwHF-based agents enrolled into the 2019 edition of Medicine Catalog for National Basic Medical Insurance, Injury Insurance, and Maternity Insurance. However, individual differences in TGT/TWT response across patients usually exist in the process of treating RA, implying that the clinical application of the two agents may not be standardized leading to the ineffective treatment and the risk of side effects. Growing evidence show that the bioactive constituents of TwHF may often have toxicity, the package insert of TGT and TWT may not be described in detail, and the therapeutic windows of the two agents are narrow. Thus, it is an urgent task to develop a standardized clinical practice guideline for TGT and TWT in the treatment of RA. In the current study, a group of clinical experts of traditional Chinese medicine and Western medicine in the research field of rheumatism diseases, pharmacists, and methodologists of evidence-based medicine were invited to select the clinical questions, to determine the levels of the evidence and the strength of the recommendations, and to develop the recommendations and good practice points. The guideline is formed based on the combination of clinical research evidence and expert experience (evidence-based, consensus, supplemented by experience). The clinical problems which are supported by clinical evidence may form recommendations, and the clinical problems without clinical evidence may form experts' suggestions. Both recommendations and experts' suggestions in this guideline summarized the clinical indications, usage, dosage, combined medication, and safety of TGT and TWT against RA systematically and comprehensively, which may offer a professional guidance in the context of the clinical application of the two TwHF-based agents.
引用
- Lin N, Zhang YQ, Jiang Q, et al. Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis. Front Pharmacol. 2021. PMID: 33519474. doi:10.3389/fphar.2020.608703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。